In recent years, pressure has increased to isolate the United States from any contact with the Chinese economy. The latest sector to be affected is health care, with proposals to ban U.S. drug companies from subcontracting various tasks to Chinese companies.Here it is economist:
The ripple effects on Chinese companies' U.S. customers are also likely to be severe. Let's start with the contract manufacturer and researcher. Wuxi is to Big Pharma what his iPhone assembler Foxconn in Taiwan is to his Apple, a high-quality supplier to whom sensitive products are entrusted. ip. The company's customers include 20 of the world's largest pharmaceutical companies. Dozens of American drug companies have notified investors: If the bill is passed, we may be unable to meet demand for our products or complete our clinical trials as scheduled. . . .
Investment bank Jefferies estimates it will take at least five years to replace China's production capacity and will almost certainly end up costing more. For biotech startups that tend to rely on proven Chinese partners to save time and money on research and manufacturing, BIOSECURE This bill could pose an existential threat. A March survey by consulting firm Biocentury found that biotech leaders and their investors expect drug development to slow if the bill passes.
It is difficult to evaluate the „national security“ argument. This is because almost everything is thought to have some kind of indirect connection with that amorphous concept. Will a weakened China therefore make war less likely because our enemies are less powerful? Or are rich countries more prone to war because they have more to lose in war?
One thing seems clear. The track record of nationalism is much less encouraging than that of internationalism.